



FINAL

Gynecologic Cancer InterGroup

RARE TUMOURS COMMITTEE
Friday, November 3, 2017, 8:00am – 9:30am
Seminarraum Room, Medical University of Vienna
Chair: J.Ledermann Co-Chair: C.Scott
Harmonization liaisons: Farrelly (Ops), Paul (Stats)

Please sign-in on attendance forms

AGENDA

Call to Order and Welcome	Ledermann
COI declarations	
Approval of Minutes/Report October 2017 (posted on GCIG website)	
Motion: _____	Seconded: _____
Closed/Published Trials: (3')	Ledermann
MEOC	
ALEINOR	
On-going clinical trials: (5')	Ledermann
EORTC 62113-55115 High Grade Uterine Sarcoma	
NiCC	
Update of trials in development: (15')	
Low Grade serous ovarian cancer (Letrozole/Chemotherapy)	Gershenson
KGOG Germ Cell Tumour	Park
Clear Cell Radiotherapy Study	McCormack
New/Concepts proposals: (40')	
Clear Cell Ovarian Cancer ENMD2076	L'heureux
ATARI (ATR inhibitor/olaparib)	Banerjee
Dysgerminoma trial (EURACAN)	Ray-Coquard
Phase II Trial of Niraparib and Everolimus in ARID1A-Mutated or Neuroendocrine GYN Cancers	Kristeleit
Future Directions: (20')	
REDCap Database update	Scott
ENGOT rare tumour update	Pignata
ESGO SoA 2018/ GCIG/ESGO Guidelines	Ledermann/ Ray-Coquard
Adjourn	